Biogen Idec rejects Carl Icahn slate

Billionaire investor Carl Icahn is mounting yet another proxy fight, this time against Biogen Idec Inc.

The company, which produces drugs to treat illnesses such as cancer and multiple sclerosis, has rejected Icahn’s board nominees. Instead, it is urging stockholders to re-elect three existing directors and also put a new fourth director on the board.

Icahn, who has a 3.5% stake in the company, has proposed three candidates, who would make up a fourth of the board. He has also threatened to nominate additional candidates next year, in an effort to seize the board majority.

Icahn has voiced disapproval with the company’s failure to complete a sale last fall.

Forbes reported today that James C. Mullen. president & CEO of Biogen Idec, received total compensation valued at nearly $10.5 million last year.

Tweet This! Share on Facebook

Click here to sign up for the Muckety Newsletter

• Icahn buys low, then takes a seat at the table - March 2, 2009
• Icahn blogs on Securities and Exchange Commission site - June 11, 2008
• Microsoft confirms it could renew its effort to buy all of Yahoo! - July 7, 2008
• Muck tracker - Carl Icahn leaving Yahoo board - October 23, 2009
• The Dons of D.R. Horton - October 4, 2007
• Richard Fuld says Lehman collapse brought on by ‘lack of confidence’ - October 6, 2008
• Directors feel First Marblehead’s pain - December 17, 2007
• Investors want shakeup at CNET - January 7, 2008
• Muckety trading: Blackrock pay and Southwest stock - April 29, 2008
• The professors of oil at ExxonMobil - April 16, 2008